Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 66
- Registration Number
- NCT04892498
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳The Sixth Affiliated Hospital ，Sun Yat-seen University, Guangzhou, China
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 6
- Registration Number
- NCT04812470
- Locations
- 🇸🇪
Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 1100
- Registration Number
- NCT04766307
- Locations
- 🇨🇳
The Infectious Hospital of Handan, Handan, Hebei, China
🇨🇳The Infectious Hospital of mudanjiang, Mudanjiang, Heilongjiang, China
🇨🇳Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT04673617
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸UF Health Shands Cancer Hospital, Gainesville, Florida, United States
NeoTIL in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 42
- Registration Number
- NCT04643574
- Locations
- 🇨🇭
centre hospitalier universitaire vaudois (CHUV), Lausanne, Vaud, Switzerland
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT04630769
- Locations
- 🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States
FT819 in Subjects With B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT04629729
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04625205
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Brussel, Belgium
🇳🇱Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04596033
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-10-31
- Target Recruit Count
- 29
- Registration Number
- NCT04562129
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.